Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Kolvenbag

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Prostate|April 30, 1999
Bicalutamide dosages used in the treatment of prostate cancerG J Kolvenbag, A Nash
European Urology|January 1, 1997
The antiandrogen withdrawal syndrome in relapsed prostate cancerH I Scher, G J Kolvenbag
Urology|January 1, 1996
Worldwide activity and safety of bicalutamide: a summary reviewG J Kolvenbag, G R Blackledge
Urology|January 1, 1996
Defining the role of antiandrogens in the treatment of prostate cancerD G McLeod, G J Kolvenbag
Urology|August 15, 2001
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancerG J Kolvenbag, P Iversen, D W Newling
The Prostate|January 15, 1998
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical developmentG J Kolvenbag, G R Blackledge, K Gotting-Smith
Journal of Immunological Methods|September 4, 1984
Molecular characterization of a membrane protein by a simple immunobinding procedure with monoclonal antibodiesA Sonnenberg, G J Kolvenbag, E J Al, et al.
Urology|March 4, 2000
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?M F Sarosdy, P F Schellhammer, R Johnson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1986
Monoclonal antibodies detecting different epitopes on the Forssman glycolipid haptenA Sonnenberg, P van Balen, T Hengeveld, et al.
Urology|December 1, 1996
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological GroupP Fernandez del Moral, G A Dijkman, F M Debruyne, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Prostate|April 30, 1999
Bicalutamide dosages used in the treatment of prostate cancerG J Kolvenbag, A Nash
European Urology|January 1, 1997
The antiandrogen withdrawal syndrome in relapsed prostate cancerH I Scher, G J Kolvenbag
Urology|January 1, 1996
Worldwide activity and safety of bicalutamide: a summary reviewG J Kolvenbag, G R Blackledge
Urology|January 1, 1996
Defining the role of antiandrogens in the treatment of prostate cancerD G McLeod, G J Kolvenbag
Urology|August 15, 2001
Antiandrogen monotherapy: a new form of treatment for patients with prostate cancerG J Kolvenbag, P Iversen, D W Newling
The Prostate|January 15, 1998
Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical developmentG J Kolvenbag, G R Blackledge, K Gotting-Smith
Journal of Immunological Methods|September 4, 1984
Molecular characterization of a membrane protein by a simple immunobinding procedure with monoclonal antibodiesA Sonnenberg, G J Kolvenbag, E J Al, et al.
Urology|March 4, 2000
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?M F Sarosdy, P F Schellhammer, R Johnson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 15, 1986
Monoclonal antibodies detecting different epitopes on the Forssman glycolipid haptenA Sonnenberg, P van Balen, T Hengeveld, et al.
Urology|December 1, 1996
Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological GroupP Fernandez del Moral, G A Dijkman, F M Debruyne, et al.
Pageof 2